KYMR | tickerfilter.com

Fundamental analysis

34%

Profitability 35%

Dept financing 22%

Liquidity 58%

Performance 31%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0.41%

1 Month

14.44%

3 Months

21.03%

6 Months

57.83%

1 Year

205.80%

2 Year

156.39%

Key data

Stock price

$88.07

P/E Ratio

0.00

DAY RANGE

$85.49 - $88.29

EPS

-$3.63

52 WEEK RANGE

$28.06 - $103.00

52 WEEK CHANGE

$186.87

MARKET CAP

5.598 B

YIELD

N/A

SHARES OUTSTANDING

81.642 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-06-2025

BETA

1.94

PUBLIC FLOAT

AVERAGE 10 VOLUME

$491,959

AVERAGE 30 VOLUME

$600,180

Company detail

CEO: Nello Mainolfi
Region: US
Website: kymeratx.com
Employees: 170
IPO year: 2020

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Kymera Therapeutics, Inc. focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases. IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the. treatment of hematologic malignancies and solid tumors.

KYMR - Kymera Therapeutics, Inc.